Amicus Therapeutics (FOLD)
(Real Time Quote from BATS)
$10.26 USD
+0.09 (0.89%)
Updated Apr 26, 2024 01:54 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
FOLD 10.26 +0.09(0.89%)
Will FOLD be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for FOLD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FOLD
Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?
Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates
FOLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates
Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why
Amicus (FOLD) Issues Preliminary Revenue Results for FY23
Other News for FOLD
Takeda said to have left industry trade group BIO
First Week of FOLD June 21st Options Trading
As more rare disease therapies launch, their prices are rising
WuXi Biologics Reports Solid 2023 Annual Results
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report